NCT05891379View on ClinicalTrials.gov

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Inebilizumab

Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.

DRUG

oral immunosuppressant

Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.

Trial Locations (1)

100053

RECRUITING

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER